Skip to content
Home
About us
Co-founders
Our Team
Our Product Pipeline
Our Technology
Scientific Advisors
Investors
Science
AMD and Eyecyte-RPE
TM
Retinitis pigmentosa and Eyecyte-PRP
TM
AAV – mediated gene therapy
Publications
Resources
News and Media
Recognition
Collaborations
Research Alliance
Careers
Contact Us
Home
About us
Co-founders
Our Team
Our Product Pipeline
Our Technology
Scientific Advisors
Investors
Science
AMD and Eyecyte-RPE
TM
Retinitis pigmentosa and Eyecyte-PRP
TM
AAV – mediated gene therapy
Publications
Resources
News and Media
Recognition
Collaborations
Research Alliance
Careers
Contact Us
Eyestem receives positive recommendation from the Drug Safety Monitoring Board(DSMB) for the first set of patient injections for its pioneering Dry AMD treatment
Home
update
Eyestem receives positive recommendation from the Drug Safety Monitoring Board(DSMB) for the first set of patient injections for its pioneering Dry AMD treatment
Post Author:
eyetem@admin
Post navigation
Previous Post
Eyestem completes first set of patient injections for its pioneering Dry AMD treatment
Next Post
Eyestem announces interim safety and efficacy data from ongoing Phase I trial using Eyecyte-RPE for the treatment of Geographic Atrophy patients, in an International Conference “The Future is Here II, Exploring New Frontiers of Ocular Research”, organized by LV Prasad Eye Institute, Hyderabad b/w Jan 9-12.
